Antiinflammatory effect of telmisartan on chronic obstructive pulmonary disease: 8-isoprostane concentration in exhaled breath condensate

Abdülkadir Geylani Şahan, Abdülkerim Yılmaz, Türker Taşlıyurt, Sibel Doruk, Handan İnönü Köseoğlu, Hakan Şıvgın, Mustafa Sağcan
1.098 445

Abstract


Abstract

Aim. Chronic obstructive pulmonary disease (COPD) is a chronic, progressive, inflammatory disease. Oxidative stress and airway inflammation are its main pathophysiologic components. In this study, our aim was to investigate the effect of an angiotensin receptor blocker (ARB) telmisartan which also exerts antiinflammatory effects on inflammation and oxidative stress in COPD. Method. The study group consisted of 50 stable COPD patients including 25 telmisartan users. Exhaled breath condensate (EBC) samples of the cases were collected using an EBC collecting device (Ecoscreen, Jaeger, Germany). EBC samples were analyzed and 8-isoprostane levels were measured using an enzyme immunoassay method (Cayman Chemical Co. Michigan, USA). Results. Any intergroup difference as for mean age, distribution of gender and smoking were not found. In telmisartan users, and nonusers mean 8-isoprostane levels were 33.98 and 35.91 pg/mL, respectively with a statistically significant intergroup difference (p<0.001) Conclusion. We think that ARBs decrease oxidative stress and inflammation, and thus exert favourable effects on the pathophysiology and progression of COPD.

Keywords: Chronic obstructive pulmonary disease, oxidative stress, 8-isoprostane, angiotensin receptor blocker, telmisartan

 

Özet

Amaç. Kronik obstrüktif akciğer hastalığı (KOAH) kronik, ilerleyici, inflamatuar bir hastalıktır. Oksidatif stres ve havayolu inflamasyonu hastalığın ana patofizyolojik etkenleridir. Bu çalışmada bir anjiyotensin reseptör blokeri (ARB) olan telmisartan’ın KOAH’daki antiinflamatuar etkisini araştırmayı amaçladık. Yöntem. Çalışmaya 25’i telmisartan kullanan 50 KOAH hastası alındı. Hastaların yoğunlaştırılmış soluk havası (EBC) örnekleri EBC toplama cihazı kullanılarak toplandı (Ecoscreen, Jaeger, Germany). EBC örnekleri analiz edildi ve enzim immunoassay metodu (Cayman Chemical Co. Michigan, USA) kullanılarak 8-izoprostan düzeyleri ölçüldü. Bulgular. Her iki grup arasında ortalama yaş, cinsiyet ve sigara kullanımı açısından fark yoktu. Telmisartan kullanan ve kullanmayan grupta 8-izoprostan düzeyleri sırasıyla 33,98 ve 35,91 pg/mL olarak ölçüldü, iki grup arasındaki fark istatistiksel olarak anlamlı bulundu (p<0,001). Sonuç. ARB’lerin oksidatif stres ve inflamasyonu azaltarak hastalığın patofizyolojisi ve ilerleyişine olumlu etkileri olabilir.

Anahtar sözcükler: Kronik obstrüktif akciğer hastalığı, oksidatif stres, 8-izoprostan, anjiyotensin reseptör blokeri, telmisartan


Keywords


Chronic obstructive pulmonary disease, oxidative stress, 8-isoprostane, angiotensin receptor blocker, telmisartan

Full Text:

PDF


DOI: http://dx.doi.org/10.7197/cmj.v36i2.1008002087

References


Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.

Global Initiative For Chronic Obstructive Lung Disease (GOLD) Updated 2008; 4: 24-30.

Owen CA. Proteinases and Oxidants as Targets in the treatment of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2005; 2: 373-85.

Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta 2005; 356: 22-34.

Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-9.

Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.

Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane inexhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-8.

Inagami T, Senbonmatsu T. Dual effects of angiotensin II type 2 receptor on cardiovascular hypertrophy. Trends Cardiovasc Med 2001; 11: 324-8.

Savoia C, Schiffrin EL. Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag 2007; 3: 975-83.

Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-8.

Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Gialernios TP. Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: The effect of smoking. J Clin Hypertens (Greenwich) 2007; 9: 21-7.

Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 2009; 27: 2365-76.

Touyz RM, Savoia C, He Y, Endemann D, Pu Q, Ko EA. Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: Improvement after angiotensin II type 1 receptor blockade. J Am Soc Hypertens 2007; 1: 189-99.

Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: Effect of angiotensin receptor blockers. Arthritis Rheum 2010; 62: 1319-28.

Dandona P, Dhindsa S, Ghanim H Chaudhuri A. Angiotensin II and inflammation: The effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21: 20-7.

Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.

Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J 2003; 21: 589-93.

ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. American Thoracic Society; European Respiratory Society Am J Respir Crit Care Med 2005; 171: 912-30.

Tian Q, Miyazaki R, Ichiki T, Imayama I, Inanaga K, Ohtsubo H. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancerbindingprotein beta. Hypertension 2009; 53: 798-804.

Benicky J, Sánchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 2009; 29: 781-92.

Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-inducedlate normal tissue injury: Therapeutic implications. Curr Med Chem 2009; 16: 130-43.

Colmenero J, Bataller R, Sancho-Bru P, Domínguez M, Moreno M, Forns X. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 2009; 297: 726-34.

Wang T, Yin KS, Liu KY, Lu GJ, Li YH, Chen JD. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats. Chin Med J (Engl) 2008;121: 2312-9.

Hagiwara S, Iwasaka H, Hidaka S, Hasegawa A, Koga H, Noguchi T. Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med 2009; 35: 1471-8.

Sakuta T. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis. American College of Rheumatology 2010; 62: 1319-28.

Gemici B, Tan R, Ongüt G, Izgüt-Uysal VN. Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemiareperfusion: Role of angiotensin II. J Surg Res 2010; 161: 126-33.

Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a metaanalysis. Thorax 2004; 59: 574-80.

Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS. C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax 2006; 61: 1-3.

Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1414-8.

Raupach T, Lüthje L, Kögler H, Duve C, Schweda F, Hasenfuss G. Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model. Pulm Pharmacol Ther 2011; 24: 215-20.

Mascitelli L, Pezzetta F. Renin-angiotensin system blockade and COPD. Chest 2006; 129: 1734-35.

Pavlishchuk SA, Bolotova EV, Porkhanov VA. Efficacy of telmisartan in chronic obstructive lung disease wtih arterial hypertension. Klin Med (Mosk) 2005; 83: 63-5.

Andreas S, Herrmann-Lingen C, Raupach T, Lüthje L, Fabricius JA, Hruska N. Angiotensin II blockers in obstructive pulmonary disease: A randomised controlled trial. Eur Respir J 2006; 27: 972-9.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.